Search alternatives:
marker decrease » marked decrease (Expand Search), larger decrease (Expand Search), marked increase (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
a marker » _ marker (Expand Search), _ markers (Expand Search)
a large » _ large (Expand Search)
b large » _ large (Expand Search), _ larger (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), c large (Expand Search)
marker decrease » marked decrease (Expand Search), larger decrease (Expand Search), marked increase (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
a marker » _ marker (Expand Search), _ markers (Expand Search)
a large » _ large (Expand Search)
b large » _ large (Expand Search), _ larger (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), c large (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Table 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx
Published 2025“…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
-
9
Data Sheet 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx
Published 2025“…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
-
10
Table1_Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy.docx
Published 2024“…Background<p>CDGSH iron-sulfur domain 2 (CISD2), an iron-sulfur protein with a [2Fe-2S] cluster, plays a pivotal role in the progression of various cancers, including Diffuse Large B-cell Lymphoma (DLBCL). …”
-
11
Image1_Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy.JPEG
Published 2024“…Background<p>CDGSH iron-sulfur domain 2 (CISD2), an iron-sulfur protein with a [2Fe-2S] cluster, plays a pivotal role in the progression of various cancers, including Diffuse Large B-cell Lymphoma (DLBCL). …”
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20